Progress in Neuro-Psychopharmacology and Biological Psychiatry

Research studies have demonstrated that persons who have Alcohol Use Disorder (AUD) exhibit a more severe progression of psychiatric disorders, indicating potential causal connections between AUD and psychiatric disorders. Identifying underlying risk variables between AUD and psychiatric problems continues to be challenging. To address these issues, we created a bioinformatics pipeline and employed network-based methods to discover genes that exhibit improper expression in both AUD and psychiatric disorders. The objective of our study was to identify common molecular pathways that may elucidate the relationship between AUD and psychiatric disorders. We identified 49 genes that were expressed differently in tissue samples of patients with both AUD and psychiatric disorders. The DAVID online platform was used to discover the most significant Gene Ontology (GO) keywords and metabolic pathways. It detected the involvement of immune response, chemokine activity, TNF signaling, IL-17 signaling, and prostaglandin signaling pathways among the common DEGs. In addition, eleven topological algorithms identified a single hub protein, specifically TTR, from the protein-protein interaction (PPI) network. Through regulatory network analysis, we identified four crucial transcription factors (TFs)--YY1, FOXC1, JUND, and GATA2--and seven miRNAs (e.g., hsa-mir-146a-5p, hsa-mir-20a-5p) that play vital roles in regulating the development of AUD and psychiatric disorders. These miRNAs may serve as potential therapeutic targets. Validation of the hub gene using ROC analysis indicated acceptable predictive performance. Our approach revealed several potential biomarkers and signaling pathways linking AUD with psychiatric disorders, offering new insights for diagnosis and treatment. HighlightsO_LIIntegration of genome-scale transcriptomic datasets with biomolecular networks identified key hub genes (TTR, SOCS3, CXCL10, MMP9, and C4A). C_LIO_LICommon transcription factors, including YY1, FOXC1, JUND, and GATA2, were uncovered as potential regulatory elements. C_LIO_LICritical miRNAs (hsa-miR-146a-5p, hsa-miR-20a-5p, hsa-miR-107, hsa-miR-124-3p, hsa-miR-138-5p, and hsa-miR-330-3p) were identified as key post-transcriptional regulators. C_LIO_LIHistone modification profiling revealed multiple modification sites in hub genes and transcription factors, linking them to Intellectual Disability, Bipolar Disorder, Schizophrenia, and Alcohol Use Disorder. C_LIO_LIProtein-drug interaction analysis highlighted 10 candidate compounds with potential therapeutic relevance for the identified markers across ID, Bipolar Disorder, Schizophrenia, and AUD. C_LI

Attention-deficit/hyperactivity disorder (ADHD) is a developmental psychiatric disorder associated with a complex interplay of genetic and environmental risk factors. We have shown embryonic dorsal forebrain loss in mice of fibroblast growth factor receptor 2 (Fgfr2), which has a critical role in normal brain development, results in ADHD-relevant phenotypes: increased locomotion and sociability, and impaired working memory postnatally. How such genetic vulnerabilities interact with environmental exposures to translationally model human ADHD risk remains unclear. Here, we pair the embryonic hGFAP-cre Fgfr2 conditional knockout (Fgfr2 cKO) mouse model with prenatal repetitive restraint stress, modeling an environmental factor associated with ADHD risk, to assess adult offspring behaviors and dopamine transporter (DAT) levels. Offspring of prenatally stressed, Fgfr2 cKO mice show increased locomotion (80% compared to non-stressed, Fgfr2 cKO animals). Prenatal stress led to a trend increase in impulsivity and trend decrease in working memory but did not affect sociability. There were no interactions with Fgfr2 cKO observed in these behaviors. Neurobiologically, prenatal stress led to a trend decrease in medial frontal cortex DAT, but these changes did not correlate with behavior. Taken together, our findings implicate prenatal stress as a potential contributor to gene-environment interactions for ADHD risk, supporting its use in translational animal models of childhood psychiatric disorders.

RationaleAttention-deficit/hyperactivity disorder (ADHD) is associated with executive dysfunction involving inattention and impulsivity, with evidence of disrupted functional expression of the dopamine and noradrenaline transporters. ObjectiveWe investigated the dose-dependent modulation of anti-ADHD drugs on selective and sustained visual attention in low-, mid-and high-attention phenotypes. Two mathematical approaches, signal detection theory and theory of visual attention were applied to further characterise the effects and mechanisms. MethodsRats were trained to detect and respond to the presence or absence of a visual target to obtain food reward on a signal detection task. After attentional performance stabilised, the indirect catecholamine agonist, d-amphetamine (0.1; 0.2; 0.4 mg/kg), the dopamine (DA) and noradrenaline (NA) reuptake inhibitor methylphenidate (0.3; 1; 3 mg/kg), and the NA reuptake inhibitor atomoxetine (0.1; 0.3; 1 mg/kg), were administered systemically. ResultsLow-dose d-amphetamine produced baseline-dependent effects on attention, improving target discrimination only in rats with lower attentive performance, whereas methylphenidate did not significantly improve attention but increased guessing. In contrast, low-dose atomoxetine selectively impaired attention in low-attentive subjects, whereas high-dose atomoxetine generally impaired discrimination performance. All three drugs had expected effects on motor response output. ConclusionsAs well as demonstrating baseline-dependent effects of amphetamine on visual attention, the findings for methylphenidate and atomoxetine suggest important, apparently opposing effects on visual signal detection performance produced via blockade of the DA and NA transporters. The deleterious effects of atomoxetine on performance were especially noteworthy in view of its use as a treatment in ADHD.

ObjectiveThe objective of this study is to provide a concise overview of the various molecular problems and possible treatment targets that have been linked and associated with the onset of certain psychiatric diseases. MethodsObtaining the data from NCBI, we applied GREIN to analyze our datasets. The protein-protein interaction, gene regulatory network, protein-drug-chemical, gene ontology, and pathway network were constructed using STRING, Funrich and DAVID libraries. In order to display our suggested network, we utilized Cytoscape and R studio, verifying our hub gene using roc analysis. ResultsWe discovered a number of strong candidate hub proteins in significant pathways, namely out of 32 (HLA-DRA, HLA-A, HLA-B, HLA-DOB and BRD2) common genes. We also identified a number of TFs (FOXC1, NFYA, RELA, GATA2, FOXL1, SRF and NFIC); miRNA (hsa-mir-129-2-3p, hsa-mir-148b-3p, hsa-mir-196a-5p, hsa-mir-26a-5p, hsa-mir-27a-3p, hsa-mir-23b-3p, hsa-mir-500a-3p, hsa-mir-423-5p, hsa-miR-142-5p, and hsa-miR-671-5p) and chemicals (Estradiol, Antirheumatic Agents, Valproic Acid, Selenium, Vitamin E, ICG 001, Ifosfamide, Tetrachlorodibenzodioxin, arsenic trioxide, entinostat, sodium arsenite and Hydralazine) may control DEGs in transcription as well as post-transcriptional expression levels. ConclusionIn summary, our computational methods have identified distinct potential biomarkers that demonstrate the impact of PTSD, Schizophrenia, and BD on autoimmune inflammation and infectious diseases. Additionally, we have identified pathways and gene regulators through which these psychiatric disorders may affect biological processes. Graphical AbstractThe graphical abstract demonstrates the thorough strategy of combining systems biology and computational technologies to identify significant markers and pathways in blood tissues impacted by post-traumatic stress disorder, Schizophrenia, and Bipolar disorder. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=152 SRC="FIGDIR/small/708243v1_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1cd13bforg.highwire.dtl.DTLVardef@cb6392org.highwire.dtl.DTLVardef@f634cforg.highwire.dtl.DTLVardef@532bd_HPS_FORMAT_FIGEXP M_FIG C_FIG

Stressors are commonly used in rats to induce models of anxiety or depression. The effectiveness of these stressors is often evaluated using specific behavioural tests. In a previous meta-analysis of chronic variable stress (CVS) procedures, we predicted that longer and more intensive stress procedures would result in larger effect sizes in behavioural tests. However, we found that the duration or intensity of CVS procedures did not correlate strongly with the magnitude of the effect sizes reported in behaviouraltests. In that study, we were concerned that the large and unexplained diversity in CVS procedure design, both in terms of duration and the types of stressors used, made it challenging to detect the factors that were influencing effect size. In an effort to address this, we explore here the use of a much simpler stress procedure - chronic restraint stress (CRS) - to study the relationship between the duration of CRS procedures and the effect sizes obtained in subsequent behavioural tests. We searched PubMed for articles using CRS procedures with rats, systematically documented the total duration of restraint, and carried out a meta-analysis of the effect sizes obtained in four behavioural tests: the forced swim test (FST), the sucrose preference test (SPT), the elevated plus maze (EPM) and the open field test (OFT). We found that chronic restraint stress increased immobility in the FST, decreased sucrose preference in the SPT, decreased time spent in the open arms of the EPM but had no effect on time spent in the centre of the OFT. However, the effect sizes in all behavioural tests, except the SPT, were not moderated by the duration of the CRS procedure, indicating that longer CRS procedures are associated with larger effect sizes in the SPT but not in the FST or EPM.

BackgroundSchizophrenia is a highly heritable mental disorder associated with widespread anatomical alterations during neurodevelopment. Converging evidence suggests transcriptomic architecture underlying brain abnormalities in schizophrenia, while how individualized brain morphological deviations relate to gene expression levels remains unclear. MethodsTo investigate individual-level brain deviations and its transcriptomic signatures in schizophrenia, this study collected T1-weighted MRI data from 95 early-onset schizophrenia (EOS) patients and 99 typically developing (TD) controls. Normative modeling was used to measure individual deviations in cortical thickness and subcortical volume. Partial least squares regression was calculated to capture covarying patterns between structural deviations and whole-brain gene expression levels. Clustering analysis was performed on latent brain-gene covarying components, and the results were further functionally decoded through gene enrichment analyses. ResultsGroup-level comparisons suggested patients with EOS showed consistently decreased z-scores of cortical thickness in the frontal and temporal lobe regions, while increased inter-individual variability in the lingual gyrus. Clustering analysis of z-scores with transcriptomic signatures identified two distinct brain-gene covarying subtypes. Subtype 1 showed thickening cingulate gyrus, thinning occipital pole, and atrophic subcortical nuclei. Subtype 2 exhibited widespread cortical thinning across the frontal, parietal, temporal, and limbic regions, but enlarged subcortical nuclei. Genes underlying two subtypes were both enriched for neurodevelopmental diseases. However, subtype 1 was associated with synaptic transmission, and subtype 2 was related to cytoskeletal and neuronal connectivity. ConclusionThis study reveals individual-level anatomical deviations and transcriptomic heterogeneity in early-onset schizophrenia. The findings provide an individualized brain-gene coupling framework for understanding pathophysiology of schizophrenia during brain development.

Schizophrenia is a serious mental disorder that changes the way people think, perceive, and manage daily life. Getting the diagnosis right is critical for proper treatment, but in practice it is often difficult. Current evaluations depend mostly on a clinicians judgment, and the overlap of symptoms with bipolar disorder or major depression makes the task even harder. EEG offers a safe and noninvasive way to study brain activity, yet no single EEG feature has been reliable enough to stand on its own. This makes it important to look at integrative approaches that bring together different aspects of brain dynamics. In this study, we analyzed EEG features to distinguish patients with schizophrenia from healthy controls. Spectral power was measured across {delta}, {theta}, , {beta}, and {gamma} bands. Temporal irregularity was quantified with Multiscale Permutation Entropy (MPE), which to our knowledge represents the first application of MPE to EEG in schizophrenia. Functional connectivity was estimated with the weighted Phase Lag Index in {theta}, , and {beta} bands, followed by extraction of graph measures including global efficiency, clustering coefficient, characteristic path length, and mean strength. These features were used to train Random Forest, Multi-Layer Perceptron, and Support Vector Machine classifiers. Among the models, Random Forest achieved the most reliable performance, reaching 99.7% accuracy under stratified 5-fold validation and 99.6% under leave-one-subject-out validation. Feature analysis showed that connectivity in {theta} and bands contributed most strongly to classification. Topographic maps of {theta}, , and {beta} activity also revealed regional group differences. Overall, the results suggest that combining spectral, entropy, and connectivity measures offers a promising framework for EEG-based detection of schizophrenia. Nevertheless, these findings are preliminary given the limited sample size (N=28), and replication in larger and more diverse cohorts is required before clinical translation.

Perceptual learning is a temporally dynamic process involving the acquisition and integration of sensory information necessary for adaptive decision making. Resolving the neural basis of perceptual learning could uncover new therapeutic targets for schizophrenia and other neurodevelopmental disorders that implicate impaired perceptual acuity. In the present study, we developed a novel touchscreen task which utilizes orientation discrimination to assess visual perceptual learning (VPL) in male and female rats. Based on previous evidence we hypothesised that VPL would depend on inhibitory neurotransmission mediated by {gamma}-amino butyric acid (GABA). Segregating subjects based on poor learning (lower tertile) and good learning (upper tertile) revealed dose-dependent improvements in VPL in poor learners following the administration of a GABA-B agonist (R-baclofen) and an 5 subunit specific GABA-A (GABRA5) positive allosteric modulator (alogabat) administered early in learning. Poor VPL performance was associated with a significant reduction in GABRA5 expression in dorsal regions of the prefrontal cortex (PFC), most notably the prelimbic cortex. Reduced GABRA5 expression in this region was co-localized to somatostatin- and parvalbumin-expressing interneurons. These findings indicate that inter-individual variation in the expression of GABRA5 in selective PFC populations of inhibitory interneurons may determine the speed and acuity of VPL. Based on these findings, interventions that restore GABRA5 signalling in the PFC may hold therapeutic relevance for neuropsychiatric disorders involving deficits in perceptual learning.

7q11.23 Duplication Syndrome (7Dup) is a type of syndromic autism spectrum disorder caused by duplication of a typically 1.5-1.8 Mb segment in section q11.23 of chromosome 7, including 25-27 genes. Previous work has highlighted the GTF2I gene as playing a major role in the phenotype of 7Dup patients. Accordingly, mice with Gtf2i duplication (Gtf2i+/dup) are commonly used as an animal model of 7Dup. We previously reported deficits in several behavioral and physiological modalities, which were associated with Gtf2i dosage in mice conducting a battery of social discrimination tests. Here, we report the effect of treating Gtf2i+/dup mice with Baicalin, a naturally occurring flavonoid added to the mices drinking water (0.15 mg/ml), on these deficits. We found that Baicalin treatment ameliorated the higher surface temperature observed in Gtf2i+/dup males and the lower tail temperature observed in Gtf2i+/dup females during the social behavior tests. It also prevented the increased defecation rate exhibited by Gtf2i+/dup mice during the social preference test. We further analyzed the effect of Baicalin treatment on cortical neurons differentiated from 7Dup patient-derived IPSCs. Using whole cell patch clamp and calcium imaging, we found an increased rate of excitatory postsynaptic currents in Baicalin-treated cells, without a change in their firing rate, indicating a stronger synaptic activity in the Baicalin-treated cells. Altogether, our results reveal that Baicalin administration alleviates some of the behavioral and physiological effects of Gtf2i duplication in mice, and affects neuronal activity in cultured 7Dup human neurons. Thus, Baicalin administration has the potential to serve as a treatment for 7Dup patients.

Cannabidiol (CBD) and Cannabigerol (CBG) are non-psychoactive cannabinoids known to affect both cancerous and non-cancerous cells. Autophagy is a critical regulator of cell survival and death; however, the impact of CBD and CBG on cell viability through autophagy remains limited. In this study, we show that low-dose combinations of CBD and CBG synergistically enhance Caco-2 cell proliferation, achieving effects comparable to those observed at higher doses. Both cannabinoids--whether applied individually at high concentrations or in low-dose combinations--activate autophagy. Correlation analyses between cell viability and autophagic flux, along with comparative assessments of wild-type and ATG9-deficient Caco-2 cells, demonstrate that the survival-promoting effects of CBD and CBG are closely associated with autophagy activation. Overall, these findings reveal that both individual and combined treatments significantly modulate Caco-2 cell viability under conditions with or without autophagy activation, emphasizing the substantial role of cannabinoid-regulated autophagy in influencing cell survival. HighlightsO_LILow-dose combinations of CBD and CBG synergistically enhance Caco-2 cell proliferation. C_LIO_LIBoth high-dose individual treatments and low-dose combinations of CBD and CBG activate autophagy. C_LIO_LICBD- and CBG-mediated autophagy paly beneficial role in supporting Caco-2 cell survival. C_LI

Anorexia nervosa is an eating disorder disproportionately found in female human teens and young adults. It is often resistant to treatment, has a significant chance of relapse and is more lethal than other eating disorders, such as bulimia nervosa or Avoidant/Restrictive Food Intake Disorder (ARFID). There is no specific medication for the treatment of anorexia nervosa. Treatment consists of psychosocial means, psychotherapy, psychoeducation, and nutritional counseling. Medication is usually used for treating comorbidities such as anxiety or to decrease obsessive-compulsive tendencies. These medications cannot help the patient regain weight or treat core symptoms. Metabotropic 2/3-glutamate (mGluR2/3) receptor agonist (LY379268) and antagonist (LY341495) are promising pharmacological agents to treat psychiatric disorders. Both agonists and antagonists have been reported to have anxiolytic effects in different animal models of anxiety, while antagonists have shown antidepressant-like effects in preclinical studies. The activity-based anorexia (ABA) paradigm is used to model anorexia nervosa. It consists of giving mice access to a running wheel and restricting their feeding time. This causes mice to exercise more than mice without feeding time restriction and to eat less than mice without access to a moving running wheel. In this study, we subcutaneously injected female ABA model mice with a metabotropic 2/3-glutamate receptor agonist (LY379268) and antagonist (LY341495) in two experiments. Both compounds exacerbated weight loss by decreasing food intake as well as increasing physical activity. It can be concluded that the manipulation of mGluR2/3 receptors is detrimental for the ABA model and likely for anorexia nervosa as well. HighlightsO_LImGluR2/3 agonist LY379268 decreases food intake and body weight of the ABA model C_LIO_LImGluR2/3 antagonist LY341495 decreases food intake and body weight of the ABA model C_LIO_LIBoth agonist and antagonist produce the effect within 48 hours C_LIO_LIBoth the agonist and antagonist are detrimental to the ABA-model C_LI

Cannabis contains many bioactive compounds, including {Delta}9-Tetrahydrocannabinol (THC) and cannabidiol (CBD), which influence behavior through complex pharmacological interactions with endogenous targets. This study examines whether CBD influences THC-induced changes in motor activity, hypothermia, and antinociception traits across different THC:CBD ratios, sexes, and genetic backgrounds. Traits were measured in C57BL/6J (B6) and DBA/2J (D2) mice of both sexes following baseline intraperitoneal (i.p.) injection of vehicle (VEH) and two consecutive daily doses of VEH or THC (10 mg/kg) alone or in combination with 0.56, 5, or 10 mg/kg CBD (THC:0.56CBD, THC:5CBD, or THC:10CBD, respectively). Motor activity and hypothermia were quantified daily from 0 to 120 min following injection and antinociception was measured daily at 60 min. We found that CBD alters THC-induced changes in motor activity and hypothermia as a function of day, dose, time, sex, and strain. In D2 females, CBD dose-dependently attenuated the hypolocomotor effects of THC immediately following acute injection and enhanced these effects later at 75 min. Following repeated exposure, CBD dose-dependently enhanced THC-induced hypolocomotion in B6 females at 75 min and in D2 males at 30 min while attenuating THC-induced hypolocomotion in D2 females immediately following injection. In D2 females, CBD dose-dependently attenuated THC-induced hypothermia at 15 min and enhanced hypothermia relative to THC at 30 min in D2 males following acute injection. After repeated exposure, CBD dose-dependently enhanced THC-induced hypothermia in B6 females at 15 min and in D2 males from 30 to 120 mins, while attenuating hypothermia in D2 females at 30 min. No significant effects of CBD on antinociception were observed. Our results indicate that CBD can modulate some THC-induced traits acutely and after repeated exposure. Regulation of THC-induced behavioral responses is dependent on CBD dose, genetic background, and sex. A candidate gene search using brain gene expression in recombinant inbred mice revealed greater genetic variation in ion channel genes relative to key metabolic genes, suggesting an underlying pharmacodynamic mechanism. Future research and validation of molecular mechanisms underlying these differences is expected to enhance our understanding of potential health risks and clinical relevance of cannabis and cannabinoid compounds containing THC and CBD.

Schizophrenia is a serious mental disorder characterized by enhanced sensory-perceptual alterations. We investigated face identity recognition in people with schizophrenia with the Facial Identity Recognition Structured Task (FIRST) develop at our laboratory. This was created with natural interference features (beard, makeup and mask). This task consists in six block-trails of six images for identity recognition. Forty three adult volunteers divided into two groups: a Health Control (HC) and a group of hospitalized patients with Schizophrenia (SchG) participated in the study. We measured the total number of correct answers as well as the average reaction time for each block. We observed significant losses in recognition of identity faces with interferences such as make up, beard and facial-mask.

Background and Hypothesis: Extracellular vesicles (EVs) are phospholipid bilayer vesicles released from cells containing proteins, lipids and nucleic acids derived from the parent cell. Alterations in miRNA expression within blood-derived EVs have been proposed as potential biomarkers of disease. Specifically, identification of differentially expressed miRNAs in patients with schizophrenia (SZ) compared to healthy individuals could be used as a "miRNA signature" to aid in diagnosis and treatment. We therefore aimed to identify differentially expressed miRNAs in plasma-derived EVs between people living with SZ and healthy controls and to correlate miRNA levels with SZ-relevant clinical measures. Study Design: Plasma-derived EVs were isolated from a cohort of 33 individuals with SZ and 34 controls. Expression of 84 miRNAs was examined using a RT-qPCR panel. Study Results: Three miRNAs (hsa-miR-30e-5p, hsa-miR-103a-3p, hsa-miR-200b-3p) were differentially expressed between controls and patients. Gene ontology analysis of putative target genes shared between these miRNAs revealed enrichment of biological process terms related to neurogenesis. Analysis of miRNA expression compared to clinical measures showed that hsa-miR-103a-3p expression was associated with working memory and negatively correlated with white matter integrity in the combined patient-control group. Conclusions: We have identified a miRNA signature for SZ in plasma-derived EVs and shown for the first time that hsa-miR-30e-5p expression is significantly increased in plasma-derived EVs in SZ. The genetic links between differentially expressed miRNAs and neurogenesis, along with the correlations of hsa-miR-103a-3p with working memory and white matter integrity may underlie the functional importance of altered expression of the identified miRNAs in SZ.

ObjectiveTobacco use is a leading cause of mortality in schizophrenia, but treatments are partially effective. Default mode network (DMN) pathology is linked to tobacco use in schizophrenia, and transcranial magnetic stimulation (TMS) applied to the DMN affects craving in schizophrenia. To advance TMS therapeutics for tobacco use in schizophrenia, we used TMS experiments to 1) determine optimal stimulation parameters then 2) compare our optimal parameters against a well-established, effective TMS intervention for craving. MethodsIn Protocol Optimization TMS, nicotine-using individuals with schizophrenia (n=10) received single sessions of DMN-targeted TMS with pre/post neuroimaging and craving assessment. Neuroimaging analysis revealed bilateral parietal DMN connectivity was associated with craving change. In Comparative Effectiveness TMS (n=62), nicotine-using individuals with schizophrenia and non-psychosis controls participated in a crossover study comparing DMN-targeted and left dorsolateral prefrontal cortex (DLFPC)-targeted TMS with pre/post neuroimaging and craving assessment. Mixed effects models were used to determine effects of target, group, and relationship between craving change and connectivity change. ResultsIn Protocol Optimization TMS, increased craving was associated with increased bilateral parietal DMN connectivity (mean pFDR<0.012, r=0.60). In Comparative Effectiveness TMS, both interventions reduced craving (DLPFC: p=0.0015; DMN: p=0.0054) and bilateral parietal DMN connectivity (DLPFC: p=0.024; DMN: p=0.022). There was an interaction of bilateral parietal DMN connectivity change, group, and age (p=0.001) where connectivity change was associated with craving change in older individuals with schizophrenia (p=0.041) but not other groups. ConclusionsBilateral parietal DMN connectivity is a novel mechanism underlying craving in schizophrenia that can be engaged for therapeutic benefit.

ObjectiveCognitive deficits are a leading cause of disability in schizophrenia and are linked to poor functional outcomes. There are no first line treatments for these deficits, and their neural basis is poorly understood. While schizophrenia is associated with widespread cognitive deficits, information processing speed is most profoundly impaired. Processing speed deficits have been associated with hyperconnectivity in the Default Mode Network (DMN). We therefore tested if modulating DMN connectivity with single or multiple sessions of transcranial magnetic stimulation (TMS) applied to an individualized DMN target would affect processing speed. MethodsIn the first study, 10 individuals with schizophrenia received single TMS sessions and underwent resting-state neuroimaging and processing speed assessment (Brief Assessment of Cognition in Schizophrenia digit symbol coding) acutely before and after each session. These sessions included excitatory (intermittent theta burst stimulation, iTBS); inhibitory (continuous theta burst stimulation, cTBS); and sham stimulation sessions. In the second study, 29 individuals (17 schizophrenia, 12 non-psychosis controls) received 5 accelerated sessions of cTBS with resting-state neuroimaging and processing speed assessment before and after the course of TMS sessions. ResultsIn the accelerated, multi-session DMN-targeted TMS trial, cTBS improved processing speed in the schizophrenia group (p=0.0124). In individuals with schizophrenia, reduction in DMN connectivity was linked to improvement in processing speed (p=0.021). These changes were dependent on age, where younger participants experienced greater processing speed improvements than older participants (p=0.006). ConclusionsIn sum, personalized network targeted TMS is a novel method for reducing cognitive impairment associated with schizophrenia.

BackgroundStructural white matter (WM) alterations are recognized in Autism Spectrum Disorder (ASD), yet the functional connectivity (FC) of WM networks and its clinical significance remain largely under-explored. MethodsThis study aimed to investigate aberrant FC patterns within intra-WM (WM-WM) and WM-gray matter (WM-GM) networks in a large ASD cohort. Resting-state fMRI data from 272 ASD individuals and 368 typical controls (TC) from the ABIDE-II dataset were analyzed. We constructed WM-WM and WM-GM FC networks using Pearson correlations between atlas-defined regions, applied ComBat harmonization, and employed Network-Based Statistics (NBS) to identify group differences. Associations with clinical symptoms were assessed using Social Responsiveness Scale (SRS) scores, and a CatBoost algorithm was used for diagnostic classification based on connectivity features. ResultsNBS analyses revealed significantly increased connectivity in ASD for 116 WM-WM pairs and 58 WM-GM pairs (P<0.05, FWER-corrected). Critically, the strength of these aberrant WM-WM functional connections exhibited a significant negative correlation with SRS total scores (r = -0.22, P < 0.001), whereas WM-GM connectivity showed no such significant association. The hybrid CatBoost classifier, integrating both WM-WM and WM-GM features, achieved moderate diagnostic discrimination (AUC = 0.669 {+/-} 0.040). ConclusionThese results offer novel insights into the aberrant functional architecture of WM-related networks in ASD, particularly linking intra-WM dysconnectivity to symptom severity, thereby enhancing our understanding of the neural substrates underlying social-communicative deficits.

Schizophrenia is associated with profound working memory deficits, for which there are no approved treatments. Rare heterozygous null mutations in SETD1A, a gene encoding a key epigenetic regulatory protein, have been definitively linked to increased risk for schizophrenia and neurodevelopmental disorders. To investigate how SETD1A haploinsufficiency impacts the function of circuits supporting working memory, this study examined neural oscillatory synchrony across a network of brain regions critical for spatial working memory (SWM) in mice carrying a loss-of-function allele in the orthologous SETD1A gene. Local field potential recordings were performed in the prefrontal cortex, dorsal and ventral hippocampus, and thalamic nucleus reuniens in male and female wildtype and Setd1a+/- mice performing a delayed non-match to sample task of SWM. Setd1a+/- mice exhibited unaltered prefrontal-hippocampal neural oscillatory synchrony across frequencies and task epochs. In contrast, Setd1a+/- mice displayed reduced beta-frequency synchrony between the prefrontal cortex and nucleus reuniens during SWM maintenance and blunted bidirectional modulation of prefrontal-reuniens beta- and gamma-frequency synchrony across SWM task epochs. Collectively, this work expands our understanding of how genetic risk for schizophrenia alters functional connectivity within distributed circuits supporting SWM. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/702577v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@8107acorg.highwire.dtl.DTLVardef@11ec407org.highwire.dtl.DTLVardef@d7ce18org.highwire.dtl.DTLVardef@1bb31f_HPS_FORMAT_FIGEXP M_FIG C_FIG

The fear circuit orchestrates defensive responses to environmental threats and is essential for survival. Dysregulation of this system is thought to contribute to the pathophysiology of several psychiatric disorders. Within this fear circuit, the corticolimbic network, particularly the amygdala and the medial prefrontal cortex (mPFC), is strongly modulated by serotonin. Previous studies have shown that Htr3a knockout (Htr3a-KO) mice exhibit deficits in the extinction of cued fear memory; however, the circuit level mechanisms underlying these impairments remain unknown. Here, we investigated this question by recording local field potentials evoked by auditory conditioned stimuli (CS) in the prelimbic (PrL), infralimbic (IL), and basolateral amygdala (BLA) of head-fixed wild-type (WT) and Htr3a-KO mice prior to fear conditioning and during fear memory retrieval. Behaviorally, Htr3a-KO mice displayed a delayed attenuation of fear-induced freezing during cued fear memory retrieval, whereas WT mice showed a rapid attenuation in freezing. Electrophysiologically, Htr3a-KO mice exhibited reduced fear-evoked theta power in the PrL, IL, and BLA, along with diminished mPFC-BLA theta synchrony. Moreover, theta-phase modulation of gamma oscillations within the BLA, which has been shown to increase during fear states, was perturbed in the absence of Htr3a signaling. Together, these findings indicate that Htr3a is critical for maintaining proper oscillatory dynamics within the mPFC-BLA circuit and for supporting effective attenuation of learned fear. Highlights- Attenuation of fear responses during fear memory retrieval sessions is protracted in Htr3a knock-out mice - The fear-induced theta response in the medial prefrontal cortex and the basolateral amygdala is less powerful in the Htr3a knock-out mice than in wild-type - Htr3a knock-out mice show a deficit in fear-induced synchronization as well as in theta modulation of gamma power in the cortico-limbic network - These results suggest that malfunction of the Htr3a receptor cause alterations in fear network circuit mechanisms that might be linked to deficits in fear responses attenuation

IntroductionWe present here a methodology for morphometric analysis of the substantia nigra (SN), the ventral tegmental area (VTA), the dorsal raphe nucleus (DRN) and their respective structural brain circuits. MethodsOur analyses were based on multimodal T1-weighted MRI and diffusion MRI (dMRI) segmentation and tractography in 12 human subjects drawn from the Human Connectome Project (HCP) repository. ResultsWe were able to demonstrate strong connections of the SN, VTA and DRN with several brain regions, in particular the dorsolateral prefrontal cortex (DLPFC) and the cerebellum. More specifically, we created comprehensive visualizations of the SN and VTA dopaminergic as well as the DRN serotonergic structural circuits in the human brain, which, although preliminary, demonstrate the potential of multimodal neuroimaging to investigate these circuits quantitatively in clinical conditions. Finally, we created a pilot dataset for the most frequently observed structural connections, specifically those that were present more than 92% of the time among all subjects. Discussion This pilot morphometric report examines the structural circuits of the SN, VTA and DRN, which are critically involved in several biobehaviors and clinical conditions such as addiction, stress, Parkinsons disease (PD), schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, mood disorders, COVID-19 and long COVID. Importantly, the strong structural connectivity of the DLPFC and cerebellum with the SN, VTA and DRN is expected to be a potential target of noninvasive neuromodulation treatments in neuropsychiatry. Our findings demonstrate the potential of current clinical multimodal neuroimaging to delineate the dopaminergic (DA) and serotonergic (5-HT) circuits in the human brain in clinical conditions.